Cover Image
市場調查報告書

全球醫藥品批發及流通市場預測:品牌/學名藥流通企業預測 - 主要企業簡介,業績及收益預測

Pharma Wholesale and Distribution Market Forecasts 2017-2027: Branded and Generic Drug Distribution, Leading National Markets, Leading Wholesalers, US, Europe, Japan and China

出版商 Visiongain Ltd 商品編碼 247784
出版日期 內容資訊 英文 265 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球醫藥品批發及流通市場預測:品牌/學名藥流通企業預測 - 主要企業簡介,業績及收益預測 Pharma Wholesale and Distribution Market Forecasts 2017-2027: Branded and Generic Drug Distribution, Leading National Markets, Leading Wholesalers, US, Europe, Japan and China
出版日期: 2017年06月22日 內容資訊: 英文 265 Pages
簡介

本報告以醫藥品的批發及流通產業為焦點,提供其市場環境,以及未來的全球、各地區、企業、領域、國家的產業收益和趨勢的市場調查資料彙整。

第1章 報告概要

第2章 市場簡介

  • 醫藥品批發業所扮演的角色
  • 流通連鎖
  • 產生收益及利益

第3章 全球醫藥品批發及流通市場

  • 全球市場
  • 全球市場預測
  • 品牌及學名藥品

第4章 醫藥品批發及流通產業:主要國家市場

  • 主要國家市場:2016年美國具優勢
  • 主要國家市場未來:美國將持續領導市場嗎?
  • 美國的醫藥品批發及流通市場
    • 財政管理法和在美國市場的效果
    • 各州不同的假藥防止法
    • 每一診療個別支付額的增加
    • 美國市場預測
  • 歐洲主要市場(歐盟五國)
    • 美國和歐洲的差異
    • 公共醫療保險和償付制度
    • 主要歐盟五國:市場預測
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本
    • 藥物價格設定和成果報酬
    • 市場預測
  • 中國
    • 主要企業
    • 市場預測
  • 巴西
    • 藥價管理
    • 主要企業
    • 市場預測
  • 印度
    • 市場預測
  • 俄羅斯
    • 藥價管理
    • 市場趨勢
    • 市場預測
  • 結論的評論

第5章 有力醫藥品批發及流通企業

  • 主要企業
  • 「收益」對「利益」
  • 主要企業:群組連合預測
  • McKesson
  • Cardinal Health
  • AmerisourceBergen
  • Walgreens Boots Alliance
  • MEDIPAL HOLDINGS CORPORATION
  • The PHOENIX Group
  • SINOPHARM
  • Alfresa Holdings
  • suzuken
  • Shanghai Pharmaceuticals Holding

第6章 定性的市場分析

  • 優勢和弱點
  • 機會及威脅
  • 市場的社會、技術、經濟、政治的影響因素(STEP分析)

第7章 調查得到的結論

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0205

The pharma wholesale and distribution market is estimated at $893.69bn in 2016 and is expected to grow at a CAGR of 6.0% in the first half of the forecast period. The market is expected to grow at a CAGR of 5.2% from 2017-2027. In 2016, the branded drugs submarket held 79.5% share of the pharma wholesale and distribution market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 265-page report you will receive 83 tables and 97 figures - all unavailable elsewhere.

The 265-page report provides clear detailed insight into the pharma wholesale and distribution market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Pharma Wholesale and Distribution market forecasts from 2017-2027

This report also breaks down the revenue forecast for main submarkets:

  • Branded Drugs
  • Generic Drugs
  • Other Medicines

This report provides individual revenue forecasts to 2027 for these national markets:

  • The US
  • Japan
  • Germany
  • France
  • Italy
  • Spain
  • The UK
  • China
  • Brazil
  • Russia
  • India

Our study includes SWOT and STEP analysis of this industry and market.

Our study discusses the selected leading companies that are the major players in the pharma wholesale and distribution industry:

  • McKesson
  • Cardinal Health
  • AmerisourceBergen
  • Walgreens Boots Alliance
  • MEDIPAL HOLDINGS
  • The PHOENIX Group
  • SINOPHARM
  • Alfresa Holdings
  • SUZUKEN
  • Shanghai Pharmaceutical Holdings

Our report explains issues, events and shifts affecting that industry and market from 2016, including these influences:

  • Roles of pharmaceutical wholesalers - activities, changes and prospects
  • Revenues, costs and profits
  • Direct-to-pharmacy (DTP) activities
  • Full-line wholesalers (FLWs), short-line wholesalers (SLWs) and the drug distribution chain, including logistical service providers
  • Technologies and services - progress in supplying pharmacies, clinics and hospitals, serving healthcare professionals, governments, payers and patients
  • Forward buying, fee-for-service systems and the rise of retail pharmacies.

Our investigation also discusses other aspects of that industry, including these forces:

  • Parallel trade - activities, policies, challenges and effects
  • Inventory management agreements, clawback, reimbursement and discounts
  • Rise of specialty medicines, including biologics, vaccines and biosimilars - opportunities for intermediaries, including cold chain distribution networks
  • Actions against drug counterfeiting - security of pharmaceutical supply chains
  • Changes to regulations and healthcare budgets - policies affecting trade

Visiongain's study is intended for anyone requiring commercial analyses for the pharma wholesale and distribution market. You find data, trends and predictions.

Buy our report today Pharma Wholesale and Distribution Market Forecasts 2017-2027: Branded and Generic Drug Distribution, Leading National Markets, Leading Wholesalers, US, Europe, Japan and China.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Pharma Wholesale and Distribution Industry and Market Overview
  • 1.2. Benefits of This Report
  • 1.3. How This Report Delivers
  • 1.4. Questions Answered by This Analytical Report
  • 1.5. Who is This Report For?
  • 1.6. Methodology
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Introduction to Pharma Wholesale and Distribution

  • 2.1. The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry
    • 2.1.1. Full-Line Wholesalers (FLWs)
    • 2.1.2. Short-Line Wholesalers (SLWs)
  • 2.2. The Chain of Distribution: Wholesalers vs. Logistic Service Providers
    • 2.2.1. Secondary Wholesalers
    • 2.2.2. Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent
    • 2.2.3. Major Wholesalers: Distribution of a Large Number of Products to Generate High Profits
    • 2.2.4. Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain
    • 2.2.5. Pharmacy Benefit Managers
  • 2.3. Generative Revenue and Profit
    • 2.3.1. Forward Buying to Avoid Price Increases
    • 2.3.2. Fee-for-Service: A Clear Pricing Structure
    • 2.3.3. Discounts: Incentives for Prompt Payment or Bulk Purchases
    • 2.3.4. Reimbursement and Wholesalers
    • 2.3.5. Clawback: The Recovery of Reimbursement Costs by Governments
    • 2.3.6. Parallel Trade: Different Attitudes in Europe and the US

3. The World Pharmaceutical Wholesale and Distribution Market: 2016-2027

  • 3.1. The World Pharmaceutical Wholesale and Distribution Market in 2015, Restricted by Government Price Reductions and Generic Substitution
  • 3.2. The Pharmaceutical Wholesale and Distribution Industry: World Market Forecast, 2016-2027
  • 3.3. Branded and Generic Drugs: Revenue vs. Profit, 2016-2027
    • 3.3.1. Branded and Generic Drugs: Revenue Generation, 2016
    • 3.3.2. Branded Drugs: Revenue Forecast, 2016-2027
    • 3.3.3. Generic Drugs: Revenue Forecast, 2016-2027

4. Pharmaceutical Wholesale and Distribution Industry: Leading National Markets, 2016-2027

  • 4.1. The Leading National Markets: the US Dominates in 2016
  • 4.2. The Future of the Leading National Markets: Will the US Continue to Dominate the Market?
  • 4.3. The US Pharma Wholesale and Distribution Market
    • 4.3.1. The Budget Control Act and its Effect on the US Wholesale and Distribution Industry
    • 4.3.2. Legislation to Prevent Counterfeit Drugs Can Differ Between States
    • 4.3.3. An Increase in Fee-For-Service Activity
    • 4.3.4. Pharma Wholesale and Distribution Market in the US: Market Forecast, 2016-2027
  • 4.4. The Leading European (EU5) Pharma Wholesale and Distribution Markets
    • 4.4.1. The Difference Between the US and European Markets
    • 4.4.2. State-Funded Healthcare and Reimbursement
    • 4.4.3. EU5: Market Forecast, 2016-2027
    • 4.4.4. Germany: Pharma Wholesale and Distribution Market, 2016
    • 4.4.5. France: Pharma Wholesale and Distribution Market, 2015
    • 4.4.6. Italy: Pharma Wholesale and Distribution Market, 2016
    • 4.4.7. Spain: Pharma Wholesale and Distribution Market, 2016
    • 4.4.8. UK: Pharma Wholesale and Distribution Market, 2016
  • 4.5. Japan: Pharma Wholesale and Distribution Market, 2016
    • 4.5.1. Drug Pricing and Performing Fees in Japan
    • 4.5.2. Japan: Pharma Wholesale and Distribution Market Forecast, 2016-2027
  • 4.6. China: Pharma Wholesale and Distribution Market, 2016
    • 4.6.1. China: Leading Pharma Wholesale and Distribution Companies, 2016
    • 4.6.2. China: Pharma Wholesale and Distribution Market Forecast, 2016-2027
  • 4.7. Brazil: Pharma and Wholesale Distribution Market, 2016
    • 4.7.1. Drug Price Controls in Brazil
    • 4.7.2. Brazil: Leading Pharma Wholesale and Distribution Companies, 2016
    • 4.7.3. Brazil: Pharma Wholesale and Distribution Market Forecast, 2016-2027
  • 4.8. India: Pharma Wholesale and Distribution Market, 2016
    • 4.8.1. India: Pharma Wholesale and Distribution Market Forecast, 2016-2027
  • 4.9. Russia: Pharma Wholesale and Distribution Market, 2016
    • 4.9.1. Drug Pricing Controls in Russia
    • 4.9.2. Market Trends in Russia
    • 4.9.3. Russia: Pharma Wholesale and Distribution Market Forecast, 2016-2027
  • 4.10. Conclusion

5. Leading Pharma Wholesalers and Distributors In 2016: Current and Future Performance

  • 5.1. The Leading Pharma Wholesalers and Distribution Companies in 2016
  • 5.2. Revenue vs. Profit
  • 5.3. Leading Pharma Wholesale and Distribution Companies: Grouped Forecasts, 2016-2027
  • 5.4. McKesson: The Oldest and Largest Healthcare Services Company in the US
    • 5.4.1. McKesson: Historical Performance, 2010-2015
    • 5.4.2. Future Strategies: Consummate Acquisitions to Complement Existing Business or Expand Businesses
    • 5.4.3. McKesson: Revenue Forecast, 2016-2027
  • 5.5. Cardinal Health: The World's Third Largest Pharma Wholesaler
    • 5.5.1. Cardinal Health: Historical Performance, 2010-2015
    • 5.5.2. Will CVS Joint Venture and Acquisitions Stimulate Future Growth?
    • 5.5.3. Cardinal Health: Revenue Forecast, 2016-2027
  • 5.6. AmerisourceBergen: Third Largest Global Pharma Wholesaler and Distributor
    • 5.6.1. AmerisourceBergen: Historical Performance, 2016
    • 5.6.2. Will Contracts with Walgreens and Alliance Boots Drive Future Growth?
    • 5.6.3. AmerisourceBergen: Revenue Forecast, 2016-2027
  • 5.7. Walgreens Boots Alliance: The Largest Drugstore Chain in the US and Global Wholesale and Distribution Network
    • 5.7.1. Walgreens Boots Alliance: Historical Performance, 2011-2016
    • 5.7.2. Acquisitions and Future Strategies of Walgreens Boots Alliance
    • 5.7.3. Walgreens Boots Alliance: Revenue Forecast, 2016-2027
  • 5.8. MEDIPAL HOLDINGS CORPORATION: Japan's Leading Pharmaceutical Wholesaler
    • 5.8.1. MEDIPAL HOLDINGS CORPORATION: Historical Performance, 2011-2015
    • 5.8.2. Future Strategies of MEDIPAL HOLDINGS CORPORATION: Revised Business Portfolio with Diverse Sources of Earnings
    • 5.8.3. MEDIPAL HOLDINGS CORPORATION: Revenue Forecast, 2016-2027
  • 5.9. Phoenix Group: Biggest European Wholesalers
    • 5.9.1. The PHOENIX Group: Historical Performance, 2011-2015
    • 5.9.2. Future Strategies of the PHOENIX Group: Selective Acquisition
    • 5.9.3. The PHOENIX Group: Revenue Forecast, 2016-2027
  • 5.10. SINOPHARM: The Leading Pharmaceutical Wholesaler and Distributor in China
    • 5.10.1. SINOPHARM: Historical Performance, 2011-2016
    • 5.10.2. Future Strategies of SINOPHARM: Provide Comprehensive Services and Wider Business Coverage
    • 5.10.3. SINOPHARM: Revenue Forecast, 2016-2027
  • 5.11. Alfresa Holdings: Second Largest Pharmaceutical Wholesaler and Distributor in Japan
    • 5.11.1. Alfresa Holdings: Historical Performance, 2011-2016
    • 5.11.2. Future Strategy of Alfresa Holdings: To Focus on Expanding Business Fields and Increasing Footprint
    • 5.11.3. Alfresa Holdings: Revenue Forecast, 2016-2027
  • 5.12. SUZUKEN CO., LTD: The First Nationwide Wholesaler of Japan
    • 5.12.1. SUZUKEN CO. LTD: Historical Performance, 2011-2015
    • 5.12.2. Future Strategies of SUZUKEN CO., LTD: Five Growth Initiatives and Special Focus on Diabetes Field
    • 5.12.3. SUZUKEN CO., LTD: Revenue Forecast, 2016-2027
  • 5.13. Shanghai Pharmaceuticals Holding: China's Second Largest Wholesaler
    • 5.13.1. Shanghai Pharmaceuticals Holding: Historical Performance, 2011-2015
    • 5.13.2. Future Strategies of Shanghai Pharma: Expansion of Three Leading Regions in China
    • 5.13.3. Shanghai Pharma: Revenue Forecast, 2016-2027

6. Qualitative Analysis of the Pharma Wholesale and Distribution Market

  • 6.1. The Strengths and Weaknesses of the Pharma Wholesale and Distribution Market, 2016
    • 6.1.1. The Insatiable Demand for Drugs: A Recession Proof Industry?
    • 6.1.2. Wholesalers Do More than Deliver Drugs
    • 6.1.3. Large Companies Dominate the Market
    • 6.1.4. Despite High Revenues, Profit Margins Are Low
    • 6.1.5. Government-Induced Drug Price Pressures Restrict Profits
    • 6.1.6. The Problem of Counterfeit Drugs
  • 6.2. The Opportunities and Threats of the Pharma Wholesale and Distribution Market, 2016-2027
    • 6.2.1. The Demand for Pharmaceuticals is Increasing
    • 6.2.2. The Increasing Use of speciality Drugs Will Drive Growth
    • 6.2.3. The Increasing Use of Generic Drugs Will Limit Revenue, But Drive Profit Generation
    • 6.2.4. The Promotion of Drug Therapy in the US
    • 6.2.5. Globalisation: The Major National Markets are Dominated by Few Companies
    • 6.2.6. Increased Adoption of the DTP Distribution Model
    • 6.2.7. The Threat of Healthcare Budget Cuts
    • 6.2.8. Do Large Pharmacy Chains Pose a Threat?
    • 6.2.9. Does the Diversion and Re-Importation of Medicines Pose a Threat to the Industry?
    • 6.2.10. The Threat of Industry Consolidation
  • 6.3. Social, Technological, Economical and Political Factors Influencing the Market, 2016-2027(STEP Analysis)
    • 6.3.1. Political Factor: The Impact of Recent Regulatory Changes in the EU
    • 6.3.2. Political Factor: Combating Counterfeit Medicines

7. Conclusions

  • 7.1. The Future of the Pharma Wholesale and Distribution Market
  • 7.2. The Leading National Pharma Wholesale and Distribution Markets
  • 7.3. The Leading Companies in the Pharma Wholesale and Distribution Industry
  • 7.4. Trends in the Pharma Wholesale and Distribution Industry
    • 7.4.1. Generics Will Threaten Revenue
    • 7.4.2. Manufacturers Will Deliver More Drugs Directly
    • 7.4.3. There Will Be Greater Demand for Speciality Medicines
    • 7.4.4. Consolidation Will Drive Growth
    • 7.4.5. Anti-Counterfeiting Demands Will Add to Wholesalers' Costs
  • Associated Visiongain Reports
  • Visiongain REPORT SALES ORDER FORM
  • APPENDIX A
  • About Visiongain
  • APPENDIX B
  • Visiongain report evaluation form

List of Tables

  • Table 1.1: Foreign Currency Exchange Rates to $US, 2016
  • Table 2.1: Use of DTP Model in the UK, 2007-2012
  • Table 3.1: Pharmaceutical Wholesale and Distribution: World Market Forecast ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 3.2: Pharmaceutical Wholesale and Distribution: Branded Drugs, Generic Drugs and Others, Revenue ($bn) Forecasts, AGR (%), CAGR (%) and Market Shares (%), 2016-2027
  • Table 3.3: Wholesale and Distribution of Branded Drugs: Revenue ($bn) and Market Share (%) Forecast, 2016-2027
  • Table 3.4: Wholesale and Distribution of Generic Drugs: Revenue ($bn) and Market Share (%) Forecast, 2016-2027
  • Table 4.1: Pharma Wholesale & Distribution Leading National Markets: Revenues ($bn) and Market Share (%), 2016
  • Table 4.2: Pharma Wholesale & Distribution Leading National Markets: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2016-2027
  • Table 4.4: US Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
  • Table 4.5: Price Controls in Europe, 2016
  • Table 4.6: EU5 Pharma Wholesale & Distribution Market: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2016-2027
  • Table 4.7: German Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
  • Table 4.8: French Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
  • Table 4.9: Italian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
  • Table 4.1: Spanish Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
  • Table 4.11: UK Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
  • Table 4.12: Percentage of the Population Ages 60+ in the US, Europe, Japan, China and India, 2015 and 2030
  • Table 4.13: Japanese Pharmaceutical Wholesale and Distribution Market: Drug Price Revision Growth (%), 2007-2016
  • Table 4.14: Japanese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
  • Table 4.15: Chinese Pharma Wholesale & Distribution: Revenue ($bn) and Market Shares (%) of Leading Companies, 2016
  • Table 4.16: Chinese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
  • Table 4.17: Brazilian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
  • Table 4.18: Indian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
  • Table 4.19: Russian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
  • Table 5.1: Leading Companies in the Pharmaceutical Wholesale and Distribution Market: Revenues ($bn) and Market Shares (%), 2016
  • Table 5.2: Leading Pharmaceutical Wholesale and Distribution Companies: Revenue Forecasts ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.3: Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%) for 2016, 2021 and 2027
  • Table 5.4: McKesson, Distribution Solutions: Services and Customers, 2016
  • Table 5.5: McKesson, Technology Solutions: Services and Customers, 2016
  • Table 5.6: McKesson: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2010-2015
  • Table 5.7: McKesson: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.8: McKesson: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.9: Acquisitions by McKesson, 2007-2017
  • Table 5.10: McKesson: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.11: Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Operating Earnings ($bn), AGR (%) and CAGR (%), 2010-2015
  • Table 5.12: Cardinal Health: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.13: Cardinal Health: Operating Earnings ($bn) and Annual Growth (%) Breakdown by Business Segment, 2014-2015
  • Table 5.14: Cardinal Health: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2015
  • Table 5.15: Selected Acquisitions by Cardinal Health and their Line of Business, 2007-2017
  • Table 5.16: Cardinal Health: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.17: AmerisourceBergen: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
  • Table 5.18: AmerisourceBergen: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
  • Table 5.19: AmerisourceBergen: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
  • Table 5.20: AmerisourceBergen: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2016
  • Table 5.21: Acquisitions by AmerisourceBergen and their Line of Business, 2007-2017
  • Table 5.22: AmerisourceBergen: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.23: Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
  • Table 5.24: Walgreens Boots Alliance: Pharmaceutical Wholesale Revenue ($bn), AGR (%), and CAGR (%) Forecast, 2016-2027
  • Table 5.25: MEDIPAL Holdings: Consolidated Subsidiary Companies, 2016
  • Table 5.26: MEDIPAL Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
  • Table 5.27: MEDIPAL Holdings: Revenue (¥bn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.28: MEDIPAL Holdings: Operating Income ($bn, ¥bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.29: MEDIPAL Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.30: PHOENIX Group: Subsidiary Companies, 2015
  • Table 5.31: PHOENIX Group: Historical Revenue (€bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (€bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
  • Table 5.32: PHOENIX Group: Revenue (€bn, $bn), Revenue Share (%) Breakdown by Region, 2014
  • Table 5.33: PHOENIX Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.34: SINOPHARM Group: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
  • Table 5.35: SINOPHARM Group: Revenue (RMBbn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
  • Table 5.36: SINOPHARM Group: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
  • Table 5.37: SINOPHARM Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.38: Alfresa Holdings: List of Significant Subsidiaries and Affiliates, 2016
  • Table 5.39: Alfresa Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
  • Table 5.40: Alfresa Holdings: Business Strategies, 2013-2016
  • Table 5.41: Alfresa Holdings: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
  • Table 5.42: Alfresa Holdings: Gross Profit (¥bn, $bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
  • Table 5.43: Alfresa Holdings: Challenges for the 16-18 Mid-term Management Plan - Break Through to Tomorrow, 2016
  • Table 5.44: Alfresa Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.45: SUZUKEN: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
  • Table 5.46: SUZUKEN: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.47: SUZUKEN: Operating Income (¥bn, $bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.48: SUZUKEN: Revenue (¥bn, $bn), Revenue Share (%) Breakdown for Pharmaceuticals Distribution Segment by Region, 2014
  • Table 5.49: SUZUKEN: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.50: Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
  • Table 5.51: Shanghai Pharmaceuticals Holding: Revenue (RMBbn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
  • Table 5.52: Shanghai Pharmaceuticals Holding: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
  • Table 5.53: Shanghai Pharmaceuticals Holding: Distribution Revenue (RMBbn, $bn), Distribution Revenue Share (%) Breakdown by Region, 2016
  • Table 5.54: Shanghai Pharmaceuticals Holding: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 6.1: The Pharmaceutical W&D Market: Strengths and Weaknesses, 2016
  • Table 6.2: The Pharmaceutical W&D Market: Opportunities and Threats, 2016-2027
  • Table 6.3: Strengths and Weaknesses of the DTP Distribution Model, 2016
  • Table 6.4: ITR Ratings and Corresponding Reimbursement Rates, 2016
  • Table 6.5: Social, Technological, Economic and Political Factors Influencing the Pharmaceutical Wholesale and Distribution Market (STEP Analysis), 2016-2027

List of Figures

  • Figure 1.1: Forecast Global Population Over the Age of 65 Years (millions), Annual Growth Rate (%), 2016-2027
  • Figure 1.2: Routes of Drug Distribution, 2016
  • Figure 2.1: Routes of Drug Distribution, 2016
  • Figure 3.1: The Global Pharmaceutical Wholesale and Distribution Market: Drivers and Restraints, 2017
  • Figure 3.2: Pharmaceutical Wholesale and Distribution: World Market Forecast ($bn), 2016-2027
  • Figure 3.3: Branded Drugs, Generic Drugs and Others: Market Shares (%), 2016
  • Figure 3.4: Branded Drugs, Generic Drugs and Others: Market Shares (%), 2021
  • Figure 3.5: Branded Drugs, Generic Drugs and Others: Market Shares (%), 2027
  • Figure 3.6: Wholesale and Distribution of Branded Drugs, Generic Drugs and Others: Revenue Forecasts ($bn), 2016-2027
  • Figure 3.7: Wholesale and Distribution of Branded Drugs: Revenue ($bn) Forecast, 2016-2027
  • Figure 3.8: Wholesale and Distribution of Generic Drugs: Revenue ($bn) Forecast, 2016-2027
  • Figure 4.1: Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2016
  • Figure 4.2: Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2021
  • Figure 4.3: Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2027
  • Figure 4.4: Market Share (%) Breakdown of the US Market: The 3 Leading Companies, 2016
  • Figure 4.5: US Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
  • Figure 4.6: US Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
  • Figure 4.7: EU5 Pharma Wholesale & Distribution Market Shares (%), 2016, 2021 and 2027
  • Figure 4.8: EU5 Pharma Wholesale & Distribution Market: Revenue ($bn) Forecasts, 2016-2027
  • Figure 4.9: EU Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
  • Figure 4.10: German Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
  • Figure 4.11: German Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
  • Figure 4.12: French Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
  • Figure 4.13: French Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
  • Figure 4.14: Italian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
  • Figure 4.15: Italian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
  • Figure 4.16: Spanish Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
  • Figure 4.17: Spanish Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
  • Figure 4.18: UK Pharma Wholesale & Distribution Market: Revenue ($bn), 2016-2027
  • Figure 4.19: UK Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
  • Figure 4.20: Percentage of the Population Ages 65+ in the US, Europe, Japan, China and India, 2015 and 2030
  • Figure 4.21: Japanese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
  • Figure 4.22: Japanese Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
  • Figure 4.23: Chinese Pharma Wholesale & Distribution: Market Shares (%) of Leading Companies, 2016
  • Figure 4.24: Chinese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
  • Figure 4.25: Chinese Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
  • Figure 4.26: Brazilian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
  • Figure 4.27: Brazilian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
  • Figure 4.28: Pharma Wholesale & Distribution Model in India, 2016
  • Figure 4.29: Indian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
  • Figure 4.30: Indian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
  • Figure 4.31: Russian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
  • Figure 4.32: Russian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
  • Figure 5.1: Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2016
  • Figure 5.2: Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2021
  • Figure 5.3: Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2027
  • Figure 5.4: Leading Pharmaceutical W&D Companies: Drivers and Restraints, 2017
  • Figure 5.5: McKesson: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2010-2015
  • Figure 5.6: McKesson: Revenue Share (%) Breakdown by Business Segment, 2015
  • Figure 5.7: McKesson: Gross Profit Share (%) Breakdown by Business Segment, 2015
  • Figure 5.8: McKesson: Revenue ($bn) Forecast, 2016-2027
  • Figure 5.9: McKesson: Drivers and Restraints, 2017
  • Figure 5.10: Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Operating Earnings ($bn) and Operating Earnings AGR(%), 2010-2015
  • Figure 5.11: Cardinal Health: Revenue Share (%) Breakdown by Business Segment, 2015
  • Figure 5.12: Cardinal Health: Revenue Share (%) Breakdown by Customer, 2015
  • Figure 5.13: Cardinal Health: Revenue ($bn) Forecast, 2016-2027
  • Figure 5.14: Cardinal Health: Drivers and Restraints, 2016-2027
  • Figure 5.15: AmerisourceBergen: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2011-2016
  • Figure 5.16: AmerisourceBergen: Revenue Share (%) Breakdown by Business Segment, 2016
  • Figure 5.17: AmerisourceBergen: Revenue ($bn) Breakdown by Customer, 2015
  • Figure 5.18: AmerisourceBergen: Revenue ($bn) Forecast, 2016-2027
  • Figure 5.19: AmerisourceBergen: Drivers and Restraints, 2017
  • Figure 5.20: Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2011-2016
  • Figure 5.21: Walgreens Boots Alliance: Revenue ($bn) Forecast, 2016-2027
  • Figure 5.22: Alliance Boots: Drivers and Restraints, 2016-2027
  • Figure 5.23: MEDIPAL Holdings: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn) and Gross Profit AGR (%), 2011-2015
  • Figure 5.24: MEDIPAL Holdings: Revenue Share (%) Breakdown by Business Segment, 2015
  • Figure 5.25: MEDIPAL Holdings: Operating Income Share (%) Breakdown by Business Segment, 2015
  • Figure 5.26: MEDIPAL Holdings: Revenue ($bn) Forecast, 2016-2027
  • Figure 5.27: MEDIPAL Holdings: Drivers and Restraints, 2017
  • Figure 5.28: PHOENIX Group: Historical Revenue (€bn), Revenue AGR (%), Gross Profit (€bn) and Gross Profit AGR (%), 2011-2015
  • Figure 5.29: PHOENIX Group: Revenue Share (%) Breakdown by Region, 2014
  • Figure 5.30: PHOENIX Group: Revenue ($bn) Forecast, 2016-2027
  • Figure 5.31: PHOENIX Group Drivers and Restraints, 2017
  • Figure 5.32: SINOPHARM Group: Historical Revenue (RMBbn), Revenue AGR (%), Gross Profit (RMBbn) and Gross Profit AGR (%), 2011-2016
  • Figure 5.33: SINOPHARM Group: Revenue ($bn) Forecast, 2016-2027
  • Figure 5.34: SINOPHARM Group: Drivers and Restraints, 2017
  • Figure 5.35: Alfresa Holdings: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn), Gross Profit AGR (%), 2011-2016
  • Figure 5.36: Alfresa Holdings: Revenue Share (%) Breakdown by Business Segment, 2016
  • Figure 5.37: Alfresa Holdings: Gross Profit Share (%) Breakdown by Business Segment, 2016
  • Figure 5.38: Alfresa Holdings: Revenue ($bn) Forecast, 2016-2027
  • Figure 5.39: Alfresa Holdings: Drivers and Restraints, 2017
  • Figure 5.40: SUZUKEN: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn) and Gross Profit AGR (%), 2011-2015
  • Figure 5.41: SUZUKEN: Revenue Share (%) Breakdown by Business Segment, 2015
  • Figure 5.42: SUZUKEN: Operating Income Share (%) Breakdown by Business Segment, 2015
  • Figure 5.43: SUZUKEN: Revenue Share (%) Breakdown by Region in Japan, 2014
  • Figure 5.44: SUZUKEN: Revenue ($bn) Forecast, 2016-2027
  • Figure 5.45: SUZUKEN: Drivers and Restraints, 2017
  • Figure 5.46: Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn), Revenue AGR (%), Gross Profit (RMBbn) and Gross Profit AGR (%), 2011-2016
  • Figure 5.47: Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Business Segment, 2016
  • Figure 5.48: Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Region, 2016
  • Figure 5.49: Shanghai Pharmaceuticals Holding: Revenue ($bn) Forecast, 2016-2027
  • Figure 5.50: Shanghai Pharmaceuticals Holding: Drivers and Restraints, 2017
  • Figure 6.1: Comparison of the Wholesale and DTP Routes of Distribution, 2016
  • Figure 7.1: Pharmaceutical Wholesale and Distribution: Global Market Forecasts ($bn) by Submarket, 2016-2027
  • Figure 7.2: Leading National Pharmaceutical Wholesale and Distribution Markets: Revenue Projections ($bn), 2016, 2021 and 2027
  • Figure 7.3: Leading Pharmaceutical Wholesale and Distribution Companies: Revenue ($bn) Projections 2016, 2021 and 2027

Companies Listed

  • 36.6 Group
  • AAH Pharmaceuticals
  • AccessClosure
  • ADG Apotheken-Dienstleistungsgesellschaft mbH
  • Admenta Italia
  • Alfresa Corporation
  • Alfresa Healthcare Corporation
  • Alfresa Holdings
  • Alfresa Medical Service Corporation
  • Alfresa Nikken Sangyo Corporation
  • Alfresa Pharma Corporation
  • Alfresa System Corporation
  • Alliance Boots
  • Alliance Healthcare
  • Alphega Network
  • AmerisourceBergen
  • Apokjeden AS
  • Apollo Medical Holdings
  • ARATA CORPORATION
  • AssuraMed
  • ASTIS Co.
  • AstraZeneca
  • Athos Farma
  • Barr Pharmaceuticals
  • Bayer
  • Biologics Inc
  • Bristol-Myers Squibb
  • Brocacef Groep NV
  • Cardinal Foods
  • Cardinal Health
  • Cardinal Health China
  • CareFusion
  • Catalent Pharma Solutions
  • Celesio AG
  • Celesio UK
  • CERP BretagneNord
  • CERP Network
  • CERP Rouen
  • China Health Systems
  • Chuo Unyu Co.
  • Cofares
  • Comifar
  • Comifar Group
  • Cordis
  • CoverMyMeds LLC
  • CS YAKUHIN CO.
  • CVS Caremark
  • Daiichi Sankyo Propharma Co
  • DEA
  • Dong Ying (Jiangsu) Pharmaceuticals Co.
  • DrogariasTamoio Network
  • Drug Trading Company
  • Emart Company
  • ERP Rhin Rhone Mediterranee
  • Express Scripts
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Guangzhou Pharmaceutical Company
  • Guangzhou Pharmaceuticals Corporation (GP Corp)
  • Hanshin Dispensing Pharmacy Holdings Co.
  • Harvard Drug
  • Healthcare Solutions Holding
  • Hefame
  • Johnson & Johnson
  • Katz Group
  • Kenzmedico Co.
  • Kinray
  • Kowa Pharmaceuticals Co.
  • Libra AG
  • Life Medicom Co.
  • LloydsPharmacy
  • McKesson
  • McQueary Brothers of Springfield
  • Medicine Shoppe Canada
  • Medipal Holdings
  • Mediq Apotheken Nederland B.V.
  • Meisho Co.
  • Metro Medical Supply
  • MSD
  • Nakano Yakuhin Co.
  • NaviHealth
  • Nihon Apoch Co
  • Nomeco
  • Novation LLC
  • Novodata Zrt
  • Odashima Limited
  • Oncology Therapeutics
  • Oncoprod
  • Outcomes Incorporated
  • P.JD. Network
  • Panpharma
  • Pfercos Co.
  • Pfizer
  • PharMEDium Healthcare Holdings
  • PHOENIX Arzneiwarengroßhandlung Ges.m.b.H.
  • PHOENIX Farmacija d.d.
  • PHOENIX Group
  • PHOENIX Lékárenský velkoobchod, a.s.
  • PHOENIX Pharma d.o.o.
  • PHOENIX Pharma DOOEL
  • PHOENIX Pharma Polska Sp. z o.o.
  • PHOENIX Pharma S.A.S
  • PHOENIX Pharma Zrt.
  • PHOENIX Pharmahandel
  • PHOENIX Zdravotnícke zásobovanie
  • Polish Pharmaceutical Council (NRA)
  • Polska Grupa Farmaceutyczna, Torfarm
  • Premium Purchasing Partners LP
  • Profarma
  • Prosper
  • Protek
  • PSS World Medical
  • QINGDAO NESCO MEDICAL CO.
  • Raintree Oncology Services
  • Ratiopharm
  • Red Oak
  • Rexall Health
  • RYUYAKU CO.
  • S.D.Next Co.
  • Sanacorp
  • Sandoz
  • Sanki Clinical Link Co.
  • Sanki Corporation
  • Sanki MediHeart Limited
  • Sanki Wellbe Co., Ltd. S-Care Mate Co.
  • Sanofi
  • Sanwa Kagaku Kenkyusho Co.
  • Sciclone Trade
  • SEIWA SANGYO CO.
  • Shanghai Pharmaceuticals
  • Shikoku Alfresa Corporation
  • Shinsegai Group
  • Shoyaku Co.
  • SIA International
  • SIA Tamro
  • SINOPHARM Group Co.
  • Sonexus Health
  • St. Francis Group
  • SUNPHARMA
  • SUZUKEN
  • Suzuken Iwate Co.
  • Suzuken Okinawa Yakuhin Co.
  • TAMPEI NAKATA CO.
  • Tamro AB
  • Tamro Eesti OÜ
  • Tamro Oyj
  • Tokiwa Yakuhin Co
  • Tradex International
  • UAB Tamro
  • US Oncology Holdings
  • Vantage Oncology
  • Walgreens
  • Walmart
  • World Courier Group
  • Wuhan Chopper Biology
  • Zuellig Pharma China

List of Organizations Mentioned in the Report

  • ACM (Authority for Consumers & Markets)
  • Asociación Cooperativas Farmacéuticas (Acofarma)
  • Bundesverband des PharmazeutischenGrosshandel (PHAGRO)
  • China National Pharmaceutical Group
  • European Association of Euro-Pharmaceutical Companies (EAEPC)
  • European Court of Justice
  • European Pharmacy Network (EPN)
  • Food and Drug Administration (US FDA)
  • Institute for Pharmaeconomic Research (IPF)
  • Japanese Pharmaceutical Wholesalers Association
  • Medicaid
  • Medicare
  • National Development and Reform Commission (NDRC)
  • National Health Insurance (NHI)
  • National Health Service (NHS)
  • National Pharmaceutical Pricing Authority (NPPA)
  • The Healthcare Distribution Management Association (HDMA)
Back to Top